Related Experiment Video
Updated: Jun 29, 2025
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases
Huifang Niu1, Minfeng Zhou2, Daniel Zogona1
1Key Laboratory of Environment Correlative Dietology (Ministry of Education), Hubei Key Laboratory of Fruit Vegetable Processing Quality Control (Huazhong Agricultural University), School of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, China.
Abstract:
Metabolic diseases are comprehensive disease based on obesity. Numerous cumulative studies have shown a certain correlation between the fluctuating abundance of Akkermansia muciniphila and the occurrence of metabolic diseases. A. muciniphila, a potential probiotic candidate colonized in the human intestinal mucus layer, and its derivatives have various physiological functions, including treating metabolic disorders and maintaining human health. This review systematically explicates the abundance change rules of A. muciniphila in metabolic diseases. It also details the high efficacy and specific molecules mechanism of A. muciniphila and its derivatives in treating obesity, type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease.
Insights
Akkermansia muciniphila abundance changes are linked to metabolic diseases. This bacterium and its derivatives show promise in treating obesity, diabetes, and cardiovascular conditions.
Area of Science:
- Microbiology
- Metabolic Disease Research
- Gut Microbiome Studies
Background:
- Metabolic diseases, often linked to obesity, show correlations with fluctuating levels of Akkermansia muciniphila.
- Akkermansia muciniphila, a gut bacterium residing in the mucus layer, is recognized for its potential probiotic properties.
- Derivatives of A. muciniphila possess physiological functions beneficial for human health.
Purpose of the Study:
- To systematically review the abundance patterns of Akkermansia muciniphila in the context of metabolic diseases.
- To detail the efficacy and molecular mechanisms of A. muciniphila and its derivatives in treating specific metabolic disorders.
- To provide insights into A. muciniphila's role in managing obesity, type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease.
Main Methods:
- Systematic literature review and analysis of studies on Akkermansia muciniphila.
- Examination of research on the physiological functions and therapeutic potential of A. muciniphila and its derivatives.
- Analysis of molecular mechanisms underlying the effects of A. muciniphila in metabolic disease models.
Main Results:
- Established correlations between altered Akkermansia muciniphila abundance and the development of metabolic diseases.
- Demonstrated high efficacy of A. muciniphila and its derivatives in preclinical and clinical studies.
- Identified specific molecular pathways targeted by A. muciniphila for therapeutic benefits.
Conclusions:
- Akkermansia muciniphila plays a significant role in metabolic health and disease.
- A. muciniphila and its derivatives represent a promising therapeutic strategy for metabolic disorders.
- Further research into A. muciniphila mechanisms can lead to novel treatments for obesity, T2DM, CVD, and NAFLD.
